BiotechTube

CT-P51 + EU-approved Keytruda

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Squamous Non Small Cell Lung Cancer

Conditions

Non Squamous Non Small Cell Lung Cancer

Trial Timeline

Jan 30, 2025 → Jul 1, 2028

NCT ID
NCT06939595

About CT-P51 + EU-approved Keytruda

CT-P51 + EU-approved Keytruda is a phase 3 stage product being developed by Celltrion for Non Squamous Non Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06939595. Target conditions include Non Squamous Non Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06939595Phase 3Recruiting

Competing Products

20 competing products in Non Squamous Non Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
Cemiplimab + CetuximabEli LillyPhase 2
52
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
52
BB-401Benitec BiopharmaPhase 2
44
Ramucirumab + PaclitaxelEli LillyPhase 2
52
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
44
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
77
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
33
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
77
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
41
Drug Combination TherapySun PharmaceuticalPhase 2
52
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + LenvatinibEisaiPhase 2
52

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85